Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues

Leukemia Research

Volumn 32, Issue 10, 2008, Pages 1573-1581

  Chen, Lisa S ^a   Plunkett, William ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cladribine; Clofarabine; Fludarabine; Nucleoside analogs; Polyadenylation inhibition; RNA processing; Transcription

Indexed keywords

CLADRIBINE; CLOFARABINE; FLUDARABINE TRIPHOSPHATE; POLYNUCLEOTIDE ADENYLYLTRANSFERASE;

ARTICLE; CONCENTRATION RESPONSE; ENZYME SPECIFICITY; POLYADENYLATION; PRIORITY JOURNAL;

ADENINE NUCLEOTIDES; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLADRIBINE; DEOXYADENINE NUCLEOTIDES; DEOXYADENOSINES; POLYADENYLATION; POLYNUCLEOTIDE ADENYLYLTRANSFERASE; SUBSTRATE SPECIFICITY;

EID: 44749088810     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.010     Document Type: Article

References (51)

1. Robak T., Korycka A., Kasznicki M., Wrzesien-Kus A., and Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Tar 5 (2005) 421-444
2. Bonate P.L., Arthaud L., Cantrell Jr. W.R., Stephenson K., Secrist III J.A., and Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5 (2006) 855-863
3. Faderl S., Gandhi V., O'Brien S., Bonate P., Cortes J., Estey E., et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105 (2005) 940-947
4. Jeha S., Gandhi V., Chan K.W., McDonald L., Ramirez I., Madden R., et al. a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103 (2004) 784-789
5. Balakrishnan K., Stellrecht C.M., Genini D., Ayres M., Wierda W.G., Keating M.J., et al. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105 (2005) 4455-4462
6. Balakrishnan K., Wierda W.G., Keating M.J., and Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res 11 (2005) 6745-6752
7. Chen L.S., and Sheppard T.L. Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C8-modified ATP analogs. J Biol Chem 279 (2004) 40405-40411
8. Huang P., Sandoval A., Van Den Neste E., Keating M.J., and Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 14 (2000) 1405-1413
9. Chen L.S., Stellrecht C.M., and Gandhi V. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol 140 (2008) 682-691
10. Gilmartin G.M. Eukaryotic mRNA 3′ processing: a common means to different ends. Genes Dev 19 (2005) 2517-2521
11. Colgan D.F., and Manley J.L. Mechanism and regulation of mRNA polyadenylation. Genes Dev 11 (1997) 2755-2766
12. Huang Y., and Carmichael G.C. Role of polyadenylation in nucleocytoplasmic transport of mRNA. Mol Cell Biol 16 (1996) 1534-1542
13. Sachs A.B., Sarnow P., and Hentze M.W. Starting at the beginning, middle, and end: translation initiation in eukaryotes. Cell 89 (1997) 831-838
14. Wilusz C.J., Wormington M., and Peltz S.W. The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2 (2001) 237-246
15. Beelman C.A., and Parker R. Degradation of mRNA in eukaryotes. Cell 81 (1995) 179-183
16. Trangas T., Courtis N., Pangalis G.A., Cosmides H.V., Ioannides C., Papamichail M., et al. Polyadenylic acid polymerase activity in normal and leukemic human leukocytes. Cancer Res 44 (1984) 3691-3697
17. Topalian S.L., Kaneko S., Gonzales M.I., Bond G.L., Ward Y., and Manley J.L. Identification and functional characterization of neo-poly(A) polymerase, an RNA processing enzyme overexpressed in human tumors. Mol Cell Biol 21 (2001) 5614-5623
18. Scorilas A., Talieri M., Ardavanis A., Courtis N., Dimitriadis E., Yotis J., et al. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: a new independent prognostic marker in primary breast cancer. Cancer Res 60 (2000) 5427-5433
19. Haff L.A., and Keller E.B. Polyadenylate polymerases from yeast. J Biol Chem 250 (1975) 1838-1846
20. Kyriakopoulou C.B., Nordvarg H., and Virtanen A. A novel nuclear human poly(A) polymerase (PAP), PAP gamma. J Biol Chem 276 (2001) 33504-33511
21. Zhelkovsky A., Helmling S., and Moore C. Processivity of the Saccharomyces cerevisiae poly(A) polymerase requires interactions at the carboxyl-terminal RNA binding domain. Mol Cell Biol 18 (1998) 5942-5951
22. Rose K.M., Bell L.E., and Jacob S.T. Specific inhibition of chromatin-associated poly(A) synthesis in vitro by cordycepin 5′-triphosphate. Nature 267 (1977) 178-180
23. Lingner J., Kellermann J., and Keller W. Cloning and expression of the essential gene for poly(A) polymerase from S. cerevisiae. Nature 354 (1991) 496-498
24. Martin G., and Keller W. Tailing and 3′-end labeling of RNA with yeast poly(A) polymerase and various nucleotides. RNA 4 (1998) 226-230
25. Ghoshal K., and Jacob S.T. Ara-ATP impairs 3′-end processing of pre-mRNAs by inhibiting both cleavage and polyadenylation. Nucleic Acids Res 19 (1991) 5871-5875
26. Martin G., Moeglich A., Keller W., Doublie S., and Biochemical. Structural insights into substrate binding and catalytic mechanism of mammalian poly(A) polymerase. J Mol Biol 341 (2004) 911-925
27. Balbo P.B., and Bohm A. Mechanism of poly(A) polymerase: structure of the enzyme-MgATP-RNA ternary complex and kinetic analysis. Structure 15 (2007) 1117-1131
28. Hoffman M.A., Janson D., Rose E., and Rai K.R. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15 (1997) 1138-1142
29. Seto S., Carrera C.J., Kubota M., Wasson D.B., and Carson D.A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75 (1985) 377-383
30. Carson D.A., Wasson D.B., Taetle R., and Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62 (1983) 737-743
31. Hentosh P., Koob R., and Blakley R.L. Incorporation of 2-halogeno-2′-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem 265 (1990) 4033-4040
32. Griffig J., Koob R., and Blakley R.L. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 49 (1989) 6923-6928
33. Parker W.B., Bapat A.R., Shen J.X., Townsend A.J., and Cheng Y.C. Interaction of 2-halogenated dATP analogs (fluoride, chloride, and bromide) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 34 (1988) 485-491
34. Van Den Neste E., Cardoen S., Husson B., Rosier J.F., Delacauw A., Ferrant A., et al. 2-Chloro-2′-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes. Leukemia 16 (2002) 36-43
35. Pettitt A.R., Clarke A.R., Cawley J.C., and Griffiths S.D. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Brit J Haematol 105 (1999) 986-988
36. Pettitt A.R., Sherrington P.D., and Cawley J.C. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Brit J Haematol 106 (1999) 1049-1051
37. Genini D., Adachi S., Chao Q., Rose D.W., Carrera C.J., Cottam H.B., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96 (2000) 3537-3543
38. Genini D., Budihardjo I., Plunkett W., Wang X., Carrera C.J., Cottam H.B., et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 275 (2000) 29-34
39. Leoni L.M., Chao Q., Cottam H.B., Genini D., Rosenbach M., Carrera C.J., et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci USA 95 (1998) 9567-9571
40. Hentosh P., and Tibudan M. In vitro transcription of DNA containing 2-chloro-2′-deoxyadenosine monophosphate. Mol Pharmacol 48 (1995) 897-904
41. Albertioni F., Lindemalm S., Reichelova V., Pettersson B., Eriksson S., Juliusson G., et al. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 4 (1998) 653-658
42. Plunkett W., Gandhi V., Huang P., Robertson L.E., Yang L.Y., Gregoire V., et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20 (1993) 2-12
43. Huang P., Chubb S., and Plunkett W. Termination of DNA synthesis by 9-β-d-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 265 (1990) 16617-16625
44. Tseng W.C., Derse D., Cheng Y.C., Brockman R.W., and Bennett Jr. L.L. In vitro biological activity of 9-β-d-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21 (1982) 474-477
45. Huang P., and Plunkett W. Action of 9-β-d-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol 39 (1991) 449-455
46. Danhauser L., Plunkett W., Keating M., and Cabanillas F. 9-Beta-d-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18 (1986) 145-152
47. Gottardi D., De Leo A.M., Alfarano A., Stacchini A., Circosta P., Gregoretti M.G., et al. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukemic B cells: in vitro/in vivo correlations. Brit J Haematol 99 (1997) 147-157
48. Xie C., and Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 55 (1995) 2847-2852
49. Parker W.B., Shaddix S.C., Chang C.H., White E.L., Rose L.M., Brockman R.W., et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51 (1991) 2386-2394
50. Gandhi V., Kantarjian H., Faderl S., Bonate P., Du M., Ayres M., et al. Pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9 (2003) 6335-6342
51. Kantarjian H., Gandhi V., Cortes J., Verstovsek S., Du M., Garcia-Manero G., et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102 (2003) 2379-2386